Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The effect of vericiguat, a novel oral soluble guanylate cyclase stimulator, in patients with heart failure and reduced ejection fraction who had recently been hospitalized or had received intravenous diuretic therapy is unclear. METHODS: In this phase 3, randomized, double-blind, placebo-controlled trial, we assigned 5 050 patients with chronic heart failure (New York Heart Association class II, III, or IV) and an ejection fraction of less than 45% to receive vericiguat (target dose 10 mg once daily) or placebo, in addition to guideline-based medical therapy.The primary outcome was a composite of death from cardiovascular causes or first hospitalization for heart failure. RESULTS: Over a median of 10.8 months, a primary-outcome event occurred in 897 of 2 526 patients (35.5%) in the vericiguat group and in 972 of 2 524 patients (38.5%) in the placebo group (p = 0.02). A total of 691 patients (27.4%) in the vericiguat group and 747 patients (29.6%) in the placebo group were hospitalized for heart failure. Death from cardiovascular causes occurred in 414 patients (16.4%) in the vericiguat group and in 441 patients (17.5%) in the placebo group. The composite endpoint of death from any cause or hospitalization for heart failure occurred in 957 patients (37.9%) in the vericiguat group and in 1 032 patients (40.9%) in the placebo group (p = 0.02). Symptomatic hypotension occurred in 9.1% of the patients in the vericiguat group and in 7.9% of the patients in the placebo group (p = 0.12), syncope occurred in 4.0% of the patients in the vericiguat group and in 3.5% of the patients in the placebo group (p = 0.30). CONCLUSION: Among patients with high-risk heart failure, the incidence of death from cardiovascular causes or hospitalization for heart failure was lower among those who received vericiguat than those who received placebo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“From a safety perspective, there was more hypotension in the vericiguat group but this did not contribute to renal dysfunction, despite the relatively low eGFR cutoff for enrollment.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [71]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Of note, the secondary end point of total HHF was also decreased in the vericiguat group (HR, 0.91 [95% CI 0.84-0.99]; P = 0.023).”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [71]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The primary combined end point of CV death or first HHF was significantly lower (HR, 0.90 [95% CI 0.82-0.98]; P = 0.019) in the vericiguat group and this was driven primarily by a reduction in hospitalization rather than CV death.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [71]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
Benjamin, E. J., Muntner, P., Alonso, A., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Das, S. R., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000659 · Cited by 9,036
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Self-citationAngiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957
Cox’s regression model for counting processes: A large sample study
Andersen, P. K., & Gill, R. D. (1982) · The Annals of Statistics · doi:10.1214/aos/1176345976 · Cited by 4,419
Heidenreich, P. A., Albert, N. M., Allen, L. A., Bluemke, D. A., Butler, J., Fonarow, G. C., Ikonomidis, J. S., Khavjou, O., Konstam, M. A., Maddox, T. M., et al. (2013) · Circulation: Heart Failure · doi:10.1161/hhf.0b013e318291329a · Cited by 2,804
Self-citationSoluble Guanylate Cyclase as an Emerging Therapeutic Target in Cardiopulmonary Disease
Stasch, J.-P., Pacher, P., & Evgenov, O. V. (2011) · Circulation · doi:10.1161/circulationaha.110.981738 · Cited by 601
Ruppar, T. M., Cooper, P. S., Mehr, D. R., Delgado, J. M., & Dunbar‐Jacob, J. M. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.115.002606 · Cited by 415
Gheorghiade, M., Greene, S. J., Butler, J., Filippatos, G., Lam, C. S. P., Maggioni, A. P., Ponikowski, P., Shah, S. J., Solomon, S. D., Kraigher-Krainer, E., et al. (2015) · JAMA · doi:10.1001/jama.2015.15734 · Cited by 397
Self-citationClinical Course of Patients With Worsening Heart Failure With Reduced Ejection Fraction
Butler, J., Yang, M., Manzi, M. A., Hess, G. P., Patel, M. J., Rhodes, T., & Givertz, M. M. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.049 · Cited by 245
Self-citationArmstrong, P. W., Roessig, L., Patel, M. J., Anstrom, K. J., Butler, J., Voors, A. A., Lam, C. S. P., Ponikowski, P., Temple, T., Pieske, B., et al. (2018) · JACC: Heart Failure · doi:10.1016/j.jchf.2017.08.013 · Cited by 208
Self-citation
Cited by
Items 201–300 of 1,000
Current Approaches to Worsening Heart Failure: Pathophysiological and Molecular Insights
D’Amato, A., Prosperi, S., Severino, P., Myftari, V., Francia, A. L., Cestiè, C., Pierucci, N., Marek‐Iannucci, S., Mariani, M. V., Germanò, R., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031574 · Cited by 36
“Results on Vericiguat were brought to light in 2020 by the VICTORIA trial [27], which included 5050 patients with chronic HF, a LVEF <45% and an episode of recent worsening HF. Re-sults Results on Vericiguat were brought to light in 2020 by the VICTORIA trial [27], which included 5050 patients with…”
BackgroundInfluentialZhang, B., Enriquez-Sarano, M. L., Schaff, H. V., Michelena, H. I., Roos, C. M., Hagler, M. A., Zhang, H., Casaclang‐Verzosa, G., Huang, R., Bartoo, A. S., et al. (2025) · Circulation · doi:10.1161/circulationaha.123.066523 · Cited by 33
Sinergy between drugs and devices in the fight against sudden cardiac death and heart failure
Boriani, G., Ponti, R. D., Guerra, F., Palmisano, P., Zanotto, G., D’Onofrio, A., & Ricci, R. P. (2020) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaa015 · Cited by 33
Visualising and understanding cGMP signals in the cardiovascular system
Feil, R., Lehners, M., Stehle, D., & Feil, S. C. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15500 · Cited by 33
Recent advances in pharmacological treatment of heart failure
Iacoviello, M., Palazzuoli, A., & Gronda, E. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13624 · Cited by 39
Chirkov, Y. Y., Nguyen, T. H. T., & Horowitz, J. D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031042 · Cited by 35
Vannuccini, F., Campora, A., Barilli, M., & Palazzuoli, A. (2022) · Biomedicines · doi:10.3390/biomedicines10102471 · Cited by 36
“In the PARADIGM-HF trial, 8442 patients were enrolled compared with 5050 patients enrolled in the VICTORIA trial and the median follow-up values were 27 months and 18 months in PARADIGM-HF and DAPA-HF trials, respectively, compared with 11 months in the VICTORIA trial [14,22,25,26].”
BackgroundMethodInfluentialAbdin, A., Bauersachs, J. K., Soltani, S., Eden, M., Frey, N., & Böhm, M. (2022) · ESC Heart Failure · doi:10.1002/ehf2.14197 · Cited by 34
“tion, a novel strategy of increasing soluble guanylate cyclase activity with vericiguat was effective.(2,7,47) The VICTORIA trial”
BackgroundMethodMauersberger, C., Sager, H. B., Wobst, J., Dang, T. A., Lambrecht, L., Koplev, S., Stroth, M., Bettaga, N., Schlossmann, J., Wunder, F., et al. (2022) · Nature Cardiovascular Research · doi:10.1038/s44161-022-00175-w · Cited by 32
Pharmacologic Treatment of Heart Failure With Reduced Ejection Fraction
van Essen, B. J., Ceelen, D. C. H., Ouwerkerk, W., Teng, T. K., Tharshana, G. N., Hew, F. M., Butler, J., Zannad, F. M., Lam, C. S. P., Ezekowitz, J. A., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.08.054 · Cited by 41
Self-citationHeart Failure With Preserved Ejection Fraction: Time for a Reset
Clark, K. A. A., & Velazquez, E. J. (2020) · JAMA · doi:10.1001/jama.2020.15566 · Cited by 35
Ameri, P., Bertero, E., Maack, C., Teerlink, J. R., Rosano, G. M. C., & Metra, M. (2021) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvab033 · Cited by 33
Current Modulation of Guanylate Cyclase Pathway Activity—Mechanism and Clinical Implications
Grześk, G., & Nowaczyk, A. (2021) · Molecules · doi:10.3390/molecules26113418 · Cited by 32
“Among patients with high-risk heart failure, the incidence of death from cardiovascular causes or hospitalization for heart failure was lower among those who received vericiguat than among those who received placebo [96].”
BackgroundBundgaard, H., Raja, A. A., Iversen, K. K., Valeur, N., Tønder, N., Schou, M., Christensen, A. H., Bruun, N. E., Søholm, H., Ghanizada, M., et al. (2022) · Circulation Heart Failure · doi:10.1161/circheartfailure.121.009120 · Cited by 33
Age, Sex, and Outcomes in Heart Failure With Reduced EF
Lam, C. S. P., Piña, I. L., Zheng, Y., Bonderman, D., Pouleur, A., Saldarriaga, C., Pieske, B. M., Blaustein, R. O., Nkulikiyinka, R., Westerhout, C. M., et al. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2023.06.020 · Cited by 31
Self-citationEffects of Heart Failure Therapies on Atrial Fibrillation: Biological and Clinical Perspectives
Mauriello, A., Ascrizzi, A., Roma, A. S., Molinari, R., Caturano, A., Imbalzano, E., D’Andrea, A., & Russo, V. (2024) · Antioxidants · doi:10.3390/antiox13070806 · Cited by 31
“This enhancement can improve myocardial function and overall cardiac performance [104].”
BackgroundResultInfluentialContemporary Management of Heart Failure in Patients With Diabetes
Shaw, J., & Cooper, M. (2020) · Diabetes Care · doi:10.2337/dc20-2173 · Cited by 22
Verma, S., Anker, S. D., Butler, J., & Bhatt, D. L. (2020) · ESC Heart Failure · doi:10.1002/ehf2.13148 · Cited by 32
Self-citationLteif, C., Ataya, A., & Duarte, J. D. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.020633 · Cited by 33
Bayés‐Genís, A., Aimo, A., Metra, M., Anker, S. D., Seferovic, P. M., Rapezzi, C., Castiglione, V., Núñez, J. E., Emdin, M., Rosano, G. M. C., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2542 · Cited by 31
Moghaddam, N., Hawkins, N. M., McKelvie, R. S., Poon, S., Joncas, S. X., MacFadyen, J. R., Honos, G. N., Wang, J., Rojas‐Fernandez, C. H., Kok, M., et al. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2022.10.013 · Cited by 31
Nakamura, T., & Tsujita, K. (2021) · Journal of Cardiology · doi:10.1016/j.jjcc.2021.03.004 · Cited by 36
Life-Prolonging Benefits of LVAD Therapy in Advanced Heart Failure
Mehra, M. R., Nayak, A., & Desai, A. S. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2023.05.013 · Cited by 28
The Ketogenic Effect of SGLT-2 Inhibitors—Beneficial or Harmful?
Koutentakis, M., Kuciński, J., Świeczkowski, D., Surma, S., Filipiak, K. J., & Gąsecka, A. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10110465 · Cited by 38
“These include angiotensin-neprilysin receptor inhibitors (ARNi) [148], SGLT-2 inhibitors, omecamtiv mecarbil (INN) [149], and vericiguat [150].”
BackgroundParadigm Shifts of Heart Failure Therapy: Do We Need Another Paradigm?
Lee, H., & Oh, B. (2020) · International Journal of Heart Failure · doi:10.36628/ijhf.2020.0010 · Cited by 30
Ilonze, O. J., Ebong, I., Guglin, M. E., Nair, A., Rich, J., McLaughlin, V., Tedford, R. J., & Mazimba, S. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.04.031 · Cited by 37
Givertz, M. M., Yang, M., Hess, G. P., Zhao, B., Rai, A., & Butler, J. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13155 · Cited by 27
“with midrange reduced ejection fraction, and several clinical trials over the last two decades have used an ejection fraction cut-off of 45%.(20,33)”
BackgroundSelf-citationHeart failure population health considerations
Patel, J. (2021) · The American Journal of Managed Care · doi:10.37765/ajmc.2021.88673 · Cited by 35
Kansakar, U., Varzideh, F., Jankauskas, S. S., Gambardella, J., Trimarco, B., & Santulli, G. (2021) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvab069 · Cited by 29
Real-World Eligibility for Vericiguat in Decompensated Heart Failure with Reduced Ejection Fraction
Oh, J., Lee, C. J., Park, J. J., Lee, S. E., Kim, M., Cho, H., Choi, J., Lee, H.-Y., Hwang, K., Kim, K. H., et al. (2022) · ESC Heart Failure · doi:10.1002/ehf2.13837 · Cited by 27
“In January 2021, vericiguat was approved by the US Food and Drug Administration (FDA) for reducing cardiovascular mortality and heart failure (HF) hospitalizations in HF patients with left ventricular ejection fraction (LVEF) <45%, requiring outpatient intravenous diuretic therapy or hospitalization, based on the Veri…”
MethodMarzo, V. D., Savarese, G., Tricarico, L., Hassan, S., Iacoviello, M., Porto, I., & Ameri, P. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13487 · Cited by 30
Lin, D. S., Lin, F., Lin, Y., Lee, J., & Lin, Y. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2740 · Cited by 29
Practical Patient Care Considerations With Use of Vericiguat After Worsening Heart Failure Events
Rao, V. N., Díez, J., Gustafsson, F., Mentz, R. J., Senni, M., Jankowska, E. A., & Bauersachs, J. K. (2022) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2022.10.431 · Cited by 26
Ltaief, Z., Yerly, P., & Liaudet, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24129971 · Cited by 32
Pamporis, K., Karakasis, P., Sagris, Μ., Zarifis, I., Bougioukas, K. I., Pagkalidou, E., Milaras, N., Samaras, A., Theofilis, P., Fragakis, N., et al. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102615 · Cited by 28
Crispino, S. P., Segreti, A., Nafisio, V., Valente, D., Crisci, F., Ferro, A., Cavallari, I., Nusca, A., Ussia, G. P., & Grigioni, F. (2025) · Biomedicines · doi:10.3390/biomedicines13030608 · Cited by 37
“Recently, following positive outcomes from the VICTORIA trial [56], evaluating the vericiguat in this setting, both the ACC [54] and the ESC [55], highlighted WHF as a distinct and clinically important phase in HF, characterized by a marked increase in adverse outcomes.”
Dapagliflozin reduces systolic blood pressure and modulates vasoactive factors
Ghanim, H., Batra, M., Green, K., HEJNA, J. M., Abuaysheh, S., Makdissi, A., Chaudhuri, A., & Dandona, P. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14377 · Cited by 29
“In addition to these changes, it is relevant that a compound, vericiguat, which stimulates GC and increases cGMP, has recently been shown to improve clinical outcomes, including hospitalization and cardiovascular death, in patients with heart failure at 3 months.(17,18) The EMPA-REG study, which first reported improve…”
BackgroundRuehs, H., Klein, D., Frei, M., Grevel, J., Austin, R. P., Becker, C., Roessig, L., Pieske, B. M., Garmann, D., & Meyer, M. C. (2021) · Clinical Pharmacokinetics · doi:10.1007/s40262-021-01024-y · Cited by 31
Self-citationRecent Insights Into Mechanisms and Clinical Approaches to Electrical Storm
Elsokkari, I., Tsuji, Y., Sapp, J. L., & Nattel, S. (2022) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2021.12.015 · Cited by 37
Kassis-George, H., Verlinden, N. J., Fu, S., & Kanwar, M. (2022) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s357422 · Cited by 35
“Two clinical trials (SOCRATES-REDUCED and VICTORIA) have evaluated the safety and efficacy of vericiguat in patients with HFrEF.”
InfluentialManagement of Heart Failure With Reduced Ejection Fraction
Rashid, A. M., Khan, M. S., Fudim, M., DeWald, T. A., DeVore, A. D., & Butler, J. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.101596 · Cited by 35
Self-citationResidual Risk in Heart Failure and the Need for Simultaneous Implementation and Innovation
Fatima, K., Butler, J., & Fonarow, G. C. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.3005 · Cited by 27
Self-citationPölzl, G., Altenberger, J., Colet, J. C., Delgado, J. F., Fedele, F., García‐González, M. J., Gustafsson, F., Masip, J., Papp, Z., Störk, S., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.3006 · Cited by 35
The evolution of small molecule enzyme activators
Dow, L. F., Case, A. M., Paustian, M. P., Pinkerton, B. R., Simeon, P., & Trippier, P. C. (2023) · RSC Medicinal Chemistry · doi:10.1039/d3md00399j · Cited by 28
Kerwagen, F., Ohlmeier, C., Evers, T., Herrmann, S., Bayh, I., Michel, A., Kruppert, S., Wilfer, J., Wachter, R., Böhm, M., et al. (2024) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-024-03654-0 · Cited by 25
Suzuki, H., Inoue, T., Terui, Y., Takeuchi, K., Susukita, K., Arai, M., Sato, H., Satoh, T., Yamamoto, S., Yaoita, N., et al. (2024) · ESC Heart Failure · doi:10.1002/ehf2.14802 · Cited by 24
Ruíz, M. G., Girón, M. F. D. S., Marco, M. D. V. G., Jorge, L. R., Saavedra, C. P., Bou, E. M., Guerra, R. A., Dorta, E. C., & Quintana, A. G. (2024) · ESC Heart Failure · doi:10.1002/ehf2.15032 · Cited by 27
“10 In fact, early initiation of vericiguat would reduce the risk of adverse events in this population.”
Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trial
Butler, J., Fioretti, F., McMullan, C., Anstrom, K., Barash, I., Bonaca, M. P., Borentain, M., Corda, S., Teixeira, P. P., Ezekowitz, J. A., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf655 · Cited by 26
“2,3,14 Vericiguat reduced the risk of cardiovascular death or hospitalization for HF in patients with NT-proBNP levels up to ∼ 8000 pg/mL.”
Self-citationAlsumali, A., Lautsch, D., Liu, R., Patel, D. A., Nanji, S., & Djatche, L. M. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01681-2 · Cited by 25
“The filing was based on findings of pivotal trial VICTORIA (NCT02861534), a phase 3, randomized, double-blind clinical trial which compared efficacy and safety between vericiguat plus GDMT and placebo plus GDMT [8].”
BackgroundMethodInfluentialTchernychev, B., Li, H., Lee, S. K., Gao, X., Ramanarasimhaiah, R., Liu, G., Hall, K. C., Bernier, S. G., Jones, J. E., Feil, S. C., et al. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15492 · Cited by 25
Aimo, A., Castiglione, V., Vergaro, G., Panichella, G., Senni, M., Lombardi, C., & Emdin, M. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10146-1 · Cited by 28
Cardiac resynchronization therapy: Current status and near-future prospects
Nakai, T., Ikeya, Y., Kogawa, R., & Okumura, Y. (2021) · Journal of Cardiology · doi:10.1016/j.jjcc.2021.10.021 · Cited by 28
Targeting mitochondrial dysfunction with elamipretide
Obi, C., Smith, A. T., Hughes, G. J., & Adeboye, A. A. (2022) · Heart Failure Reviews · doi:10.1007/s10741-021-10199-2 · Cited by 27
“Whereas recent studies of other novel medications, such as vericiguat [70] and omecamtiv mecarbil [71], have been underwhelming, demonstrating no evident mortality benefit in patients with heart failure with reduced ejection fraction despite promising pre-clinical results, the true effectiveness of elamipretide in thi…”
ResultVericiguat: A Review in Chronic Heart Failure with Reduced Ejection Fraction
Kang, C., & Lamb, Y. N. (2022) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-022-00538-5 · Cited by 31
“The difference in the cumulative incidence of CV death or first HHF with vericiguat versus placebo appeared after ≈ 3 months of treatment and persisted throughout the trial [18].”
BackgroundMethodInfluentialWang, X., Zhang, C., & Editing Group of the Chinese Expert Consensus on the Diagnosis and Treatment of Chronic Heart Failure in Elderly Patients (2022) · Aging Medicine · doi:10.1002/agm2.12215 · Cited by 27
Johansen, N. D., Vaduganathan, M., Zahir, D., Fiuzat, M., DeFilippis, E. M., Januzzi, J. L., Butler, J., O’Connor, C. M., Abraham, W. T., Psotka, M. A., et al. (2023) · Circulation Heart Failure · doi:10.1161/circheartfailure.122.009729 · Cited by 26
Self-citationEssandoh, K., Subramani, A., Ferro, O. A., Teuber, J. P., Koripella, S., & Brody, M. J. (2023) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2022.11.003 · Cited by 23
Chiang, C., Hung, C., Wu, Y., Lin, T., Ueng, K., Sung, S., Wu, C., Chao, T., Lin, H., Lin, Y., et al. (2023) · PubMed Central · doi:10.6515/acs.202305_39(3).20230301a · Cited by 30
Saldarriaga, C., Zannad, F. M., McMullan, C. J., Xing, A., Gates, D. F., Anstrom, K. J., Bonaca, M. P., Corda, S., Ezekowitz, J. A., Lam, C. S. P., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3598 · Cited by 27
Self-citationEffect of Vericiguat on Total Heart Failure Events in Compensated Outpatients With HFrEF
Zannad, F. M., Reddy, Y. N. V., Barash, I., Anstrom, K. J., Bonaca, M. P., Borentain, M., Corda, S., Teixeira, P. P., Ezekowitz, J. A., Gates, D. F., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.08.051 · Cited by 28
Self-citationCappannoli, L., Scacciavillani, R., Rocco, E., Perna, F., Narducci, M. L., Vaccarella, M., D’Amario, D., Pelargonio, G., Massetti, M., Crea, F., et al. (2020) · Heart Failure Reviews · doi:10.1007/s10741-020-10030-4 · Cited by 25
“The therapy for patients with heart failure with reduced ejection fraction (HFrEF) over the last decade has done impressive and unexpected progress so that the best HFrEF treatment now includes angiotensin receptor neprilysin inhibitor (ARNI; sacubitril/valsartan) [5], beta-blockers, mineralocorticoid receptor antagon…”
BackgroundHeart Failure With Mid-range Ejection Fraction: A Distinctive Subtype or a Transitional Stage?
Zhou, Q., Li, P., Zhao, H., Xu, X., Li, S., Zhao, J., Xu, D., & Zeng, Q. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.678121 · Cited by 31
“In the VICTORIA study, which enrolled >5,000 patients with chronic HF and an LVEF of ≤45%, vericiguat was associated with a reduced risk of CV death or HF hospitalization (92).”
Steinberg, R., Udeshi, E., Dickert, N. W., Quyyumi, A. A., Chirinos, J. A., & Morris, A. A. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.027666 · Cited by 25
“33 A recent animal model using in-vasively recorded data demonstrated that vericiguat substantially reduced wave reflection, 34 suggesting that this hemodynamic mechanism may underlie at least some of the therapeutic effect of vericiguat in HFrEF.”
MethodTreatment Strategies of Improving Quality of Care in Patients With Heart Failure
Kim, S.-E., & Yoo, B. (2023) · Korean Circulation Journal · doi:10.4070/kcj.2023.0024 · Cited by 28
MacDonald, B. J., Virani, S., Zieroth, S. R., & Turgeon, R. D. (2023) · CJC Open · doi:10.1016/j.cjco.2023.05.008 · Cited by 30
“Vericiguat is unanimously recommended for patients with “recently worsened” HF, although only the CCS also requires HF hospitalization within the past 6 months, reflecting the 84% of participants included based on this criterion in the landmark Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejecti…”
BackgroundBackground Medical Therapy and Clinical Outcomes From the VICTORIA Trial
Ezekowitz, J. A., McMullan, C. J., Westerhout, C. M., Piña, I. L., Lopez-Sendon, J. L., Anstrom, K. J., Hernandez, A. F., Lam, C. S. P., O’Connor, C. M., Pieske, B. M., et al. (2023) · Circulation Heart Failure · doi:10.1161/circheartfailure.123.010599 · Cited by 24
Self-citationSabouret, P. F., Galati, G., Angoulvant, D., Андреевна, Г. О., Castelletti, S., Pathak, A., Metra, M., & Margonato, A. (2020) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa051 · Cited by 24
“269).(43,44) The secondary EP All-cause Mortality was not reduced as well (HR = 0.”
BackgroundNitric Oxide Signaling and Sensing in Age-Related Diseases
Mazuryk, O., Gurgul, I., Oszajca, M., Polaczek, J., Kieca, K., Bieszczad-Żak, E., Martyka, T., & Stochel, G. (2024) · Antioxidants · doi:10.3390/antiox13101213 · Cited by 36
Volpe, M., Bauersachs, J. K., Bayés‐Genís, A., Butler, J., Solal, A. C., Gallo, G., Deichl, A. S., Khan, M. S., Battistoni, A., Pieske, B. M., et al. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.11.071 · Cited by 23
Self-citationVericiguat in patients with heart failure and reduced ejection fraction
Špinar, J., Špinarová, L., & Vítovec, J. (2021) · Vnitřní lékařství · doi:10.36290/vnl.2021.041 · Cited by 23
The Efficacy and Safety of Sacubitril/Valsartan in Heart Failure Patients: A Review
Zhang, R., Sun, X., Li, Y., He, W.-Z., Zhu, H., Liu, B., & Zhang, A. (2022) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484211058681 · Cited by 34
“The VICTORIA study showed that vericiguat, a novel oral soluble guanylate cyclase stimulator, decreased the composite of death from any cause or hospitalization among high-risk HF patients.(7) Importantly, sacubitril/valsartan, a firstin-class angiotensin receptor-neprilysin inhibitor (ARNI, formerly known as LCZ696),…”
Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Treatment
Youn, J., Kim, D., Cho, J. Y., Cho, D., Park, S. M., Jung, M., Hyun, J., Cho, H., Park, S., Choi, J., et al. (2023) · Korean Circulation Journal · doi:10.4070/kcj.2023.0047 · Cited by 23
Zhang, H., Xie, S., & Deng, W. (2024) · Biomolecules · doi:10.3390/biom14121614 · Cited by 24
cGMP and mitochondrial K+ channels—Compartmentalized but closely connected in cardioprotection
Łukowski, R., Santos, M. C., Kuret, A., & Ruth, P. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15536 · Cited by 28
“Both agents rely on different strategies to augment cardiac cGMP signalling path- ways as outlined in Sections 3 and 4 of this review (Armstrong et al., 2020; McMurray et al., 2014b).”
Timely and individualized heart failure management: need for implementation into the new guidelines
Abdin, A., Bauersachs, J. K., Frey, N., Kindermann, I., Link, A., Marx, N., Lainščak, M., Slawik, J., Werner, C. M., Wintrich, J., et al. (2021) · Clinical Research in Cardiology · doi:10.1007/s00392-021-01867-2 · Cited by 24
“In light of these encouraging results, the VICTORIA trial was designed to include patients with more severe HF, some of whom were randomized immediately after acute decompensation [21].”
MethodMarkousis‐Mavrogenis, G., Tromp, J., Ouwerkerk, W., Ferreira, J. P., Anker, S. D., Cleland, J. G. F., Dickstein, K., Filippatos, G. S., Lang, C. C., Metra, M., et al. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab235 · Cited by 26
Self-citationPost-myocardial Infarction Heart Failure: A Review on Management of Drug Therapies
Swaroop, G. (2022) · Cureus · doi:10.7759/cureus.25745 · Cited by 28
“Vericiguat Global Study in Subjects with HFrEF (VICTORIA) [21] trial of 4872 patients with HFrEF.”
BackgroundGrześk, G., Witczyńska, A., Węglarz, M., Wołowiec, Ł., Nowaczyk, J., Grześk, E., & Nowaczyk, A. (2023) · Molecules · doi:10.3390/molecules28020861 · Cited by 28
Applicability of Vericiguat to Patients Hospitalized for Heart Failure in the United States
Khan, M. S., Xu, H., Fonarow, G. C., Lautsch, D., Hilkert, R. J., Allen, L. A., DeVore, A. D., Alhanti, B., Yancy, C. W., Albert, N. M., et al. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2022.11.007 · Cited by 22
Self-citationNguyen, N. V., Lindberg, F., Benson, L., Ferrannini, G., Imbalzano, E., Mol, P. G. M., Dahlström, U., Rosano, G. M. C., Ezekowitz, J. A., Butler, J., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2939 · Cited by 25
Self-citationVericiguat — Another Victory for Targeting Cyclic GMP in Heart Failure
Burnett, J. C. J. (2020) · New England Journal of Medicine · doi:10.1056/nejme2006855 · Cited by 22
Chew, D. S., Li, Y., Bigelow, R., Cowper, P. A., Anstrom, K. J., Daniels, M. R., Davidson-Ray, L. D., Hernandez, A. F., O’Connor, C. M., Armstrong, P. W., et al. (2023) · Circulation · doi:10.1161/circulationaha.122.063602 · Cited by 22
Self-citationGill, H., Chehab, O., Allen, C. J., Patterson, T., Redwood, S. R., Rajani, R., & Prendergast, B. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2097 · Cited by 25
Ferguson, S. K., Woessner, M. N., Holmes, M. J., Belbis, M. D., Carlström, M., Weitzberg, E., Allen, J. D., & Hirai, D. M. (2021) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00780.2020 · Cited by 24
Nelissen, E., Argyrousi, E. K., van Goethem, N. P., Zhao, F., Hines, C. D. G., Swaminath, G., Gerisch, M., Hueser, J., Sandner, P., & Prickaerts, J. (2021) · Biomedicines · doi:10.3390/biomedicines9081047 · Cited by 25
“Additionally, a pivotal phase 3 clinical trial with vericiguat for the treatment of heart failure (HFrEF) has successfully been completed [41].”
BackgroundNeues zur Diagnostik und Therapie der Herzinsuffizienz
Wintrich, J., Berger, A.-K., Bewarder, Y., Emrich, I. E., Slawik, J., & Böhm, M. (2021) · Herz · doi:10.1007/s00059-021-05062-x · Cited by 39
“1437pg/ml. Passend dazu zeichneten sich die Patienten in VICTORIA [57] durch ein grundsätzlich hohes absolutes Risiko aus.”
BackgroundInfluentialDrug Treatment of Heart Failure with Reduced Ejection Fraction: Defining the Role of Vericiguat
Coats, A. J. S., & Tolppanen, H. (2021) · Drugs · doi:10.1007/s40265-021-01586-y · Cited by 21
“Vericiguat is a novel oral stimulator of sGC that has shown promising results as a treatment for HFrEF in the recent VICTORIA trial [1].”
BackgroundResultSmooth muscle cell CYB5R3 preserves cardiac and vascular function under chronic hypoxic stress
Durgin, B. G., Wood, K. C., Hahn, S. A., McMahon, B., Baust, J., & Straub, A. C. (2021) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2021.09.005 · Cited by 21
Zhu, G., Ueda, K., Hashimoto, M., Zhang, M., Sasaki, M., Kariya, T., Sasaki, H., Kaludercic, N., Lee, D., Bedja, D., et al. (2021) · FEBS Letters · doi:10.1002/1873-3468.14228 · Cited by 24
Inhaled mosliciguat (BAY 1237592): targeting pulmonary vasculature via activating apo-sGC
Becker‐Pelster, E., Hahn, M. G., Delbeck, M., Dietz, L., Hüser, J., Kopf, J., Kræmer, T., Marquardt, T., Mondritzki, T., Nagelschmitz, J., et al. (2022) · Respiratory Research · doi:10.1186/s12931-022-02189-1 · Cited by 23
“The sGC stimulator riociguat is approved as treatment for PAH and for chronic thromboembolic pulmonary hypertension (CTEPH) that is inoperable by pulmonary endarterectomy (PEA) or with persistent/recurrent PH after PEA [6–10], and vericiguat demonstrated positive results in a phase III heart failure trial and was very…”
BackgroundEmerging Therapy for Diabetic Cardiomyopathy: From Molecular Mechanism to Clinical Practice
Hsuan, C., Teng, S. I. F., Hsu, C., Liao, D., Chang, A. J.-W., Lee, H.-L., Hee, S., Chang, Y., & Chuang, L. (2023) · Biomedicines · doi:10.3390/biomedicines11030662 · Cited by 25
Cardiorenal syndrome and diabetes: an evil pairing
Méndez, A. B., Vergara, A., Olivella, A., Azancot, M. A., Soriano-Colomé, T., & Soler, M. J. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1185707 · Cited by 24
Gawryś, O., Husková, Z., Škaroupková, P., Honetschlägerová, Z., Vaňourková, Z., Kikerlová, S., Melenovský, V., Bačová, B. S., Sýkora, M., Táborský, M., et al. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02561-y · Cited by 23
“Low BP is a common symptom in subjects with HFrEF (around 10–15”
BackgroundInfluentialDalal, J. J., Chandra, P., Ray, S., Hazra, P. K., Hiremath, J., Kumar, V., Shah, M., Abdullakutty, J., Ghosh, D., Vasudevan, K., et al. (2023) · Cardiology and Therapy · doi:10.1007/s40119-023-00323-8 · Cited by 21
“WHF should be recognized as a clinical condition to firstly optimize existing GDMT (ARNI, beta-blocker, SGLT2 inhibitor and MRA) if possible and secondly add novel drug that improve patient outcomes [25].”
MethodInfluentialPathophysiology of Advanced Heart Failure
Biegus, J., Niewiński, P., Josiak, K., Kulej, K., Ponikowska, B., Nowak, K., Zymliński, R., & Ponikowski, P. P. (2021) · Heart Failure Clinics · doi:10.1016/j.hfc.2021.06.001 · Cited by 25
Self-citationThe Role of sGC Stimulators and Activators in Heart Failure With Reduced Ejection Fraction
Cordwin, D. J., Berei, T. J., & Pogue, K. T. (2021) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484211042706 · Cited by 21
“Given that sGC stimulators offer a unique mechanism compared to existing HFrEF therapies and the VICTORIA-HF population was considered to be more acutely ill based on required enrollment BNP levels, recent hospitalization, and/or the need for recent IV diuretic administration, there may be a potential role for vericig…”
BackgroundMethodInfluentialA year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021
Kayki‐Mutlu, G., Aksoyalp, Z. Ş., Wojnowski, L., & Michel, M. C. (2022) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-022-02250-2 · Cited by 22
Zhang, Z., Zheng, Y., He, W., Wei, J., Li, P., Zhong, G., & Jiang, Z. (2024) · ESC Heart Failure · doi:10.1002/ehf2.14814 · Cited by 20
“29,30 These novel drugs for intervention of HF may lead to signi fi cant effect on the strategy of management for AF patients with HF in the future.”
BackgroundOskouie, S. K., Pandey, A., Sauer, A. J., Greene, S. J., Müllens, W., Khan, M. S., Quinn, K. L., Ho, J. E., Albert, N. M., & Spall, H. G. C. V. (2024) · JACC Advances · doi:10.1016/j.jacadv.2024.101131 · Cited by 26
Next-generation therapeutics for diabetic kidney disease
Yi, T. W., Sridhar, V. S., Scott, J., Nardone, M., & Cherney, D. Z. I. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-025-01042-0 · Cited by 28
Metadata
- Authors
- Armstrong, P. W., Pieske, B., Anstrom, K. J., Ezekowitz, J., Hernandez, A. F., Butler, J., Lam, C. S. P., Ponikowski, P., Voors, A. A., Jia, G., McNulty, S. E., Patel, M. J., Roessig, L., Koglin, J., & O’Connor, C. M.
- Affiliations
- University of Alberta (CA)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Inova Health System (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-05-14
- Volume
- 382
- Issue
- 20
- Pages
- 1883-1893
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3013207865
- Semantic Scholar
- f98a684f8b44644864e75febeca130b492e75a2c
- Cited by
- 1,358
- References
- 17
- Citations by year
- 2026: 170 · 2025: 213 · 2024: 189 · 2023: 253 · 2022: 225 · 2021: 207 · 2020: 96
- FWCI
- 121.19
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion, other-oa)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- HAL (submittedVersion)
- Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Bayer
- Merck
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Keywords
- vericiguat, heart failure with reduced ejection fraction, soluble guanylate cyclase stimulator, cardiovascular mortality, heart failure hospitalization, symptomatic hypotension, syncope, chronic heart failure
- MeSH terms
- Soluble Guanylyl Cyclase, Administration, Oral, Aged, Cardiovascular Diseases, Chronic Disease, Double-Blind Method, Female, Follow-Up Studies, Heart Failure, Heterocyclic Compounds, 2-Ring, Hospitalization, Humans, Hypotension, Male, Middle Aged, Pyrimidines, Stroke Volume, Syncope, Incidence, Ventricular Dysfunction, Left
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.